← Back to Search

Virus Therapy

HIV Vaccine for Human Immunodeficiency Virus Infection

Phase 1
Waitlist Available
Led By Marina Caskey, MD
Research Sponsored by International AIDS Vaccine Initiative
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 months

Summary

This trial is testing a new HIV vaccine in healthy adults who do not have HIV. The vaccine works by teaching the immune system to recognize and fight HIV.

Eligible Conditions
  • Human Immunodeficiency Virus (HIV) Infection
  • HIV Suppression

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Safety - Grade 2 or greater unsolicited AEs
Safety - IP related SAEs
Safety - IP related unsolicited adverse events
+2 more
Secondary study objectives
Immunogenicity - Frequency Ab responses
Immunogenicity - Magnitude Ab responses

Trial Design

2Treatment groups
Experimental Treatment
Group I: Investigational Product, 300 µg/ PlaceboExperimental Treatment2 Interventions
300 µg IM, months 0, 2 and 6
Group II: Investigational Product, 30 µg/ PlaceboExperimental Treatment2 Interventions
30 µg IM, months 0, 2 and 6
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted
2020
Completed Phase 1
~50
Placebo
1995
Completed Phase 3
~2670

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

International AIDS Vaccine InitiativeLead Sponsor
51 Previous Clinical Trials
13,468 Total Patients Enrolled
George Washington UniversityOTHER
254 Previous Clinical Trials
466,547 Total Patients Enrolled
Rockefeller UniversityOTHER
160 Previous Clinical Trials
16,478 Total Patients Enrolled
GlaxoSmithKlineIndustry Sponsor
4,812 Previous Clinical Trials
8,382,200 Total Patients Enrolled
Amsterdam UMC, location VUmcOTHER
413 Previous Clinical Trials
216,691 Total Patients Enrolled
Marina Caskey, MDPrincipal InvestigatorRockefeller University
15 Previous Clinical Trials
695 Total Patients Enrolled
Godelieve de Bree, MD, PhDPrincipal InvestigatorAmsterdam UMC, location VUmc
1 Previous Clinical Trials
24 Total Patients Enrolled
David Joseph Diemert, MDPrincipal InvestigatorGeorge Washington University

Media Library

BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04224701 — Phase 1
Human Immunodeficiency Virus Infection Research Study Groups: Investigational Product, 300 µg/ Placebo, Investigational Product, 30 µg/ Placebo
Human Immunodeficiency Virus Infection Clinical Trial 2023: BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted Highlights & Side Effects. Trial Name: NCT04224701 — Phase 1
BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04224701 — Phase 1
~9 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top